ArticleJournal of hepatocellular carcinoma2025
Treatment Outcomes of Systemic Therapies for Infiltrative Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Outcomes in the treatment of unresectable infiltrative hepatocellular carcinoma (HCC) are poorly understood, and infiltrative HCC is generally underrepresented in clinical trials. The present study explored outcomes associated with the treatment of infiltrative HCC with various systemic therapies. Patients and Methods: We enrolled all patients with Barcelona Clinic Liver Cancer stage C infiltrative or multinodular HCC who received first-line systemic therapy between January 2015 and December 2021 at a single center. We compared baseline characteristics and treatment outcomes for the two HCC subtypes. Results: In total, 260 patients were enrolled, 128 (49.2%) of whom had infiltrative HCC. Patients with infiltrative HCC were more likely to have macrovascular invasion (91.4% vs 68.2%, Conclusion: In patients receiving ICI-based therapy for HCC, infiltrative HCC was associated with poorer outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.